Coya completes enrollment in ALS trial, data due early Q2 2027

Coya Therapeutics enrolled 120 participants in its Phase 2/3 ALSTARS trial of investigational COYA 302 for ALS. The randomized, placebo-controlled study’s primary endpoint is change in ALSFRS-R score at 24 weeks, with topline data expected in early Q2 2027; enrollment remains open to eligible participants in screening. COYA 302 is not approved, and Coya retains U.S. clinical-development and regulatory responsibilities under its partnership with Dr. Reddy’s.

Analysis

Enrollment progress reduces execution risk—especially the risk that recruitment delays push the readout—but does not de-risk efficacy. Without the planned enrollment target, it is not possible to infer how close recruitment is to completion. The key near-term variables are enrollment pace, discontinuations, and whether the company maintains its stated readout window; the main value-inflecting evidence remains the controlled 24-week ALSFRS-R result, not enrollment itself.

For COYA, the long gap to data leaves substantial time for trial execution risk and potential financing needs to affect the equity; verify cash runway and trial costs before treating the update as fundamental value creation. Fast Track may help the review process if data support an application, but it does not establish efficacy or approval probability. For RDY, the partnership offers potential downstream participation, but the article provides no terms or economics to support a material earnings impact today. The second-order competitive risk is a high bar for differentiation: even a favorable result must show a clinically meaningful signal against placebo and fit within a changing ALS treatment landscape.

The contrarian read is that a mildly positive enrollment headline can be mistaken for evidence of clinical success. Near-term price response may fade absent a recruitment target, runway disclosure, or other independently verifiable milestone. The thesis strengthens with timely enrollment completion and credible trial updates; it weakens if recruitment slips, cash runway becomes constrained, or the eventual endpoint fails to separate meaningfully from placebo.

Key Decisions for Investors

• No event-driven position is warranted on enrollment alone. Treat COYA as a clinical-catalyst watch rather than an efficacy-backed long; the principal readout is expected in early Q2 2027.
• Before sizing COYA exposure, verify the planned enrollment target, current cash runway, quarterly cash burn, and any trial-cost obligations. Reassess if runway appears insufficient to reach topline data without financing.
• Monitor for recruitment completion, discontinuation rates, trial-design changes, and timing updates. A missed readout window or material protocol change would undermine the execution de-risking thesis.
• Do not use this update to underwrite RDY earnings: partnership economics and any expected contribution are unspecified. Revisit only if disclosures quantify development obligations, milestones, royalties, or commercialization economics.